These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 3907953)
21. Defective natural killer (NK) and killer (K) cell function in systemic lupus erythematosus. Ewan PW; Barrett HM; Pusey CD J Clin Lab Immunol; 1983 Feb; 10(2):71-6. PubMed ID: 6842577 [TBL] [Abstract][Full Text] [Related]
22. [Antibody-dependent and natural cellular cytotoxic reactions in rheumatic diseases]. Aleksandrova EN; Zimin IuI; Nasonov EL Ter Arkh; 1984; 56(10):130-6. PubMed ID: 6084315 [No Abstract] [Full Text] [Related]
23. Antibodies to ribosomal ribonucleoprotein. Prevalence in systemic rheumatic diseases and partial characterization of the antigen. Cortés JJ; Mendoza F; Reyes PA J Rheumatol; 1987 Aug; 14(4):727-31. PubMed ID: 3118019 [TBL] [Abstract][Full Text] [Related]
24. [Sharp's syndrome. Clinical, immunological and nosographic aspects]. Scagliusi P; Muratore M; Martiradonna A; Berlingerio G; Carrozzo M Minerva Med; 1980 Dec; 71(50):3655-63. PubMed ID: 6161325 [TBL] [Abstract][Full Text] [Related]
25. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Banica L; Besliu A; Pistol G; Stavaru C; Ionescu R; Forsea AM; Tanaseanu C; Dumitrache S; Otelea D; Tamsulea I; Tanaseanu S; Chitonu C; Paraschiv S; Balteanu M; Stefanescu M; Matache C Autoimmunity; 2009 Jan; 42(1):41-9. PubMed ID: 18800250 [TBL] [Abstract][Full Text] [Related]
26. Natural killer cells and interferon responses in patients with systemic lupus erythematosus. Tsokos GC; Rook AH; Djeu JY; Balow JE Clin Exp Immunol; 1982 Nov; 50(2):239-45. PubMed ID: 6817954 [TBL] [Abstract][Full Text] [Related]
27. Impaired indomethacin-boosting of the defective natural killer cell activity in patients with primary Sjögren's syndrome. Pedersen BK; Oxholm P; Manthorpe R; Andersen V Scand J Rheumatol Suppl; 1986; 61():135-8. PubMed ID: 3473621 [TBL] [Abstract][Full Text] [Related]
28. Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Szodoray P; Gal I; Barath S; Aleksza M; Horvath IF; Gergely P; Szegedi G; Nakken B; Zeher M Scand J Rheumatol; 2008; 37(3):205-12. PubMed ID: 18465456 [TBL] [Abstract][Full Text] [Related]
29. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. Goules A; Tzioufas AG; Manousakis MN; Kirou KA; Crow MK; Routsias JG J Autoimmun; 2006 May; 26(3):165-71. PubMed ID: 16621447 [TBL] [Abstract][Full Text] [Related]
30. Abnormal macrophages and NK cell cytotoxicity in human systemic lupus erythematosus and the role of interferon and serum factors. Zippel D; Lackovic V; Kocisková D; Rovenský J; Borecký L; Stelzner A Acta Virol; 1989 Sep; 33(5):447-53. PubMed ID: 2483602 [TBL] [Abstract][Full Text] [Related]
31. [Hemorheologic disturbances and circulating immune complexes in patients with rheumatic diseases]. Loskutova TT; Koreshkov GG; Nasonov EL; Zakharchenko VN; Larionov SM Ter Arkh; 1989; 61(5):51-5. PubMed ID: 2781490 [No Abstract] [Full Text] [Related]
32. Ro(SSA) and La(SSB) antibodies in the clinical spectrum of Sjögren's syndrome. Alexander EL; Hirsch TJ; Arnett FC; Provost TT; Stevens MB J Rheumatol; 1982; 9(2):239-46. PubMed ID: 7097683 [TBL] [Abstract][Full Text] [Related]
33. Autoantibodies to tissue transglutaminase in Sjögren's syndrome and related rheumatic diseases. Luft LM; Barr SG; Martin LO; Chan EK; Fritzler MJ J Rheumatol; 2003 Dec; 30(12):2613-9. PubMed ID: 14719202 [TBL] [Abstract][Full Text] [Related]
35. Comparison of natural killing with antibody dependent cell mediated cytotoxicity in patients with systemic lupus erythematosus. Kozlowski SH; Hirsen DJ; Jackson EJ J Rheumatol; 1982; 9(1):59-62. PubMed ID: 7086780 [TBL] [Abstract][Full Text] [Related]
36. [Undifferentiated connective tissue disease: clinical and serological profile of 578 patients followed for five years: disease course, prognosis and therapy]. Bodolay E; Szegedi G Orv Hetil; 2002 Feb; 143(5):229-33. PubMed ID: 11875835 [TBL] [Abstract][Full Text] [Related]
37. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. Yabuhara A; Yang FC; Nakazawa T; Iwasaki Y; Mori T; Koike K; Kawai H; Komiyama A J Rheumatol; 1996 Jan; 23(1):171-7. PubMed ID: 8838528 [TBL] [Abstract][Full Text] [Related]
38. CXCL10 and autoimmune diseases. Lee EY; Lee ZH; Song YW Autoimmun Rev; 2009 Mar; 8(5):379-83. PubMed ID: 19105984 [TBL] [Abstract][Full Text] [Related]
39. Regulation of natural killer cell activity by macrophages in the rheumatoid joint and peripheral blood. Combe B; Pope R; Darnell B; Kincaid W; Talal N J Immunol; 1984 Aug; 133(2):709-13. PubMed ID: 6429243 [TBL] [Abstract][Full Text] [Related]
40. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Shibatomi K; Ida H; Yamasaki S; Nakashima T; Origuchi T; Kawakami A; Migita K; Kawabe Y; Tsujihata M; Anderson P; Eguchi K Arthritis Rheum; 2001 Apr; 44(4):884-92. PubMed ID: 11315928 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]